A meta-analysis of the effect of Sjögren’s syndrome on adverse pregnancy outcomes

Baoqing Geng, Keyue Zhang, Xianqian Huang, Yong Chen*

Department of Rheumatology and Immunology, Ningbo Huamei hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, China

HIGHLIGHTS

• Dry syndrome can increase the risk of spontaneous abortion and preterm delivery.
• Dry syndrome can increase the risk of low birth weight and birth defects.
• Clinics should provide comprehensive prenatal counseling and testing for the patients.

ARTICLE INFO

Objective: This study aimed to assess the correlation between Sjögren’s Syndrome (SS) and adverse pregnancy outcomes, with the aim of providing a basis for preconception and pregnancy interventions in women with SS.

Methods: A search of electronic databases in English and Chinese databases from January 2005 to December 2021, was conducted to collect the literature of case-control studies or cohort studies on the association between SS and pregnancy outcome studies. Literature inclusion and data extraction were performed according to established criteria, and the Newcastle-Ottawa scale was used to evaluate the quality of the literature. Stata 15 software was used for meta-analysis.

Results: A total of nine papers were included in this study. Meta-analysis results showed that SS was associated with spontaneous abortion (RR = 8.85, 95% CI 3.10–25.26), preterm birth (RR = 2.27, 95% CI 1.46–3.52), low birth mass (RR = 1.99, 95% CI 1.34–2.97), and birth defects (RR = 4.28, 95% CI 3.08–5.96).

Conclusion: SS can increase the incidence of adverse pregnancy outcomes.

Keywords: Sjögren’s syndrome
Pregnancy outcome
Meta-analysis

Introduction

Sjögren Syndrome (SS) is a systemic immune disease, mainly characterized by the impairment or absence of secretory gland function leading to pathological damage in the oral cavity and eyes, and also involving other tissues and organs of the body. Antibody testing revealed positive anti-Ro/SSA and anti-La/SSB antibodies.1 When SS occurs alone, it is primary Sjögren’s Syndrome (pSS), and when it coexists with other connective tissue diseases such as Rheumatoid Arthritis (RA), it is secondary Sjögren’s syndrome (SSS).2 The prevalence of SS ranges from 0.29% to 0.77% and is significantly higher in women than in men (gender ratio: 1.9:20), making it a life-threatening event for women.3

SS is an autoimmune disease with a good prognosis, and most of them can be remitted after standardized treatment, but patients with combined visceral damage can experience relapse after discontinuation of the drug. In early clinical practice, most SS patients were diagnosed at the age of 40–50 years, so its effect on pregnancy was not taken seriously. However, in recent years, women’s reproductive age has been higher, coupled with the enhanced public awareness of early diagnosis and early treatment, more than 25% of SS patients are diagnosed before the age of 35,4 so its impact on pregnancy has gradually been paid attention to. Recent studies have shown that SS may be associated with adverse pregnancy outcomes, and those antinuclear antibodies, anti-SSA, and anti-SSB in women during pregnancy may affect fetal development and increase the risk of adverse pregnancy outcomes such as miscarriage, congenital heart block, and preterm delivery.5

In this study, the authors intend to investigate the effect of SS on pregnancy outcomes through a literature review and meta-analysis in order to provide a basis for the management of women with SS during pregnancy.

Materials and methods

Literature search strategy

The databases including CNKI, Wanfang Database, Cqvip Database, PubMed, Web of Science, Embase and Cochrane Library were searched.
The search terms were as follows: (1) SS; (2) Pregnancy, pregnancy outcome; (3) Spontaneous abortion, preterm birth, low birth weight, congenital malformation, birth defect, congenital heart disease, congenital heart block; the combination of (1)+(2) or (1)+(3) was searched. The NoteExpress library was used for the removal of duplicate articles. This study is a literature review and has no ethical implications. The review was conducted according to PRISMA 2020 statement.

Inclusion criteria

(1) A case-control study or a cohort study; (2) The publication time of the literature: January 2005 to March 2022; (3) The patients in the case group were diagnosed with pSS, and the control group consisted of healthy pregnant women; (4) The literature was in Chinese or English; (5) At least one of the following outcomes was described: (a) Spontaneous abortion: miscarriage within 28-weeks of gestation without any interventions; (b) Birth defect: morphological, structural and functional abnormalities, including congenital heart disease, Down’s syndrome, harelip, thalassemia, malformations of the digestive system, malformations of the genitourinary system polydactyly, etc.; (c) Low birth weight: < 2500g; (d) Premature birth: gestational age < 37-weeks.

Exclusion criteria

(1) Duplicate reports for the same study population. In this case, the literature with the largest sample size was included; (2) Study subjects with other autoimmune diseases, such as systemic lupus erythematosus; (3) Studies with design flaws; (4) Incomplete data on outcome indicators; (5) Incorrect statistical methods; (6) Literature review studies, conference reports, animal experiments, clinical interventional studies.

Literature data extraction

Two investigators independently conducted literature screening and extracted data from the included literature and negotiated to resolve disagreements. A data collection form was developed, and the extracted data from the included literature and negotiated to resolve disagreements reports, animal experiments, clinical interventional studies.

Risk of bias assessment

The Newcastle-Ottawa Scale (NOS), which includes three dimensions of study subject selection, comparability between groups, and exposure factor measurement, was used, with a maximum score of 9. A score of ≥ 7 was considered high-quality literature.

Statistical analysis

Stata15 software was used for data analysis. Relative Risk (RR) was used as an effect statistic for each outcome indicator (spontaneous abortion, preterm birth, birth defects, and low birth weight). A Chi-Square test was used to analyze the heterogeneity of the literature, combined with I² values. Outcome indicators with p > 0.1 and I² < 50% were used for meta-analysis using a fixed-effects model; outcome indicators with p < 0.1 and I² > 50% were used for meta-analysis using a random-effects model. Publication bias was analyzed using Begg’s test with Egger’s test. Statistical significance was considered at p < 0.05.

Results

Basic characteristics of the included literature

The study cumulatively included nine eligible papers, two in Chinese and seven in English. Two were prospective studies, and seven were retrospective studies. NOS scores: 1 with a score of 5, 3 with a score of 6, and 5 with a score of 7; 5 pieces of literature were of high quality (≥ 7). The PRISMA flowchart is shown in Figure 1, and the basic information of the included literature is shown in Table 1.

Spontaneous abortion

Five papers described the occurrence of spontaneous abortion in pregnant women with pSS, and the results of the random effects model showed a significantly increased risk of spontaneous abortion in pregnant women with pSS (RR = 8.85, 95% CI 3.10 ~ 25.26) (Fig. 2).

Preterm birth

Nine papers described the association of pSS with preterm birth. The random effects model showed that pSS significantly increased the risk of preterm birth (RR = 2.27, 95% CI 1.46~3.52) (Fig. 3).

Low birth weight

Five papers described the correlation between pSS and low birth mass. The results of the fixed effects model showed that pSS increased the risk of low birth mass (RR = 1.99, 95% CI 1.34~2.97) (Fig. 4).

Birth defects

Four papers described the effect of pSS on the occurrence of birth defects. The results of the fixed-effects model showed that pSS significantly increased the risk of birth defects (RR = 4.28, 95% CI 3.08~5.96) (Fig. 5).

Sensitivity analysis

In the meta-analysis of the correlation between pSS and spontaneous abortion, preterm birth, low birth weight, and congenital malformation, the literature with the largest RR value and the smallest RR value were excluded and then meta-analysis was performed to compare the RR values with 95% CI before and after the exclusion, and the results are shown in Table 2. The results of sensitivity analysis showed that the correlation between pSS and spontaneous abortion, preterm birth, low birth weight, and congenital malformation was still statistically significant after the exclusion of literature, and the changes of RR values were relatively small, suggesting that the results of the original meta-analysis were reliable.

Analysis of publication bias

The publication bias was quantified using Begg’s test and Egger’s test, and the results of Egger’s test showed that there was a publication bias in the meta-analysis of the correlation between pSS and spontaneous abortion (p = 0.016), while there was no publication bias for the rest of the outcome indicators (p > 0.05). The specific data are shown in Table 3.

Discussion

SS can lead to the involvement of many exocrine glands and tissues, and the placenta is also one of the target organs during pregnancy, and placental dysfunction can occur after injury, and maternal IgG such as anti-SSA, anti-SSB, and anti-nuclear antibodies can also enter the fetus through the placental barrier and affect its intrauterine development, leading to a variety of adverse pregnancy outcomes such as miscarriage, congenital malformations, stillbirth, and preterm delivery. SS can also increase the risk of multiple pregnancy comorbidities, such as preeclampsia and premature rupture of membranes, and increase the incidence of complications such as postpartum deep vein thrombosis, thereby affecting maternal health and pregnancy outcomes.
Pregnancy itself can also have an impact on SS progression, with approximately 30% of SS patients experiencing disease exacerbation during pregnancy, causing significant increases in anti-SSA and anti-SSB levels, and decreases after the termination of pregnancy. It has also been found that a small percentage of women with SS can also develop anti-erythrocyte antibodies during pregnancy, along with the aggregation of cytokines such as IL-4, leading to comorbidities such as hemolytic anemia and lymphohistiocytic hyperplasia. All of these phenomena can negatively affect pregnancy and increase the risk of adverse pregnancy outcomes.

Some studies have evaluated the association of pSS with adverse pregnancy outcomes, but its risk is difficult to assess relative to the general population, mainly because of the high number of confounding factors such as age, body mass index, and comorbidities, and the difficulty of dealing with confounding factors. C Ballester et al. balanced common confounding factors and found that pSS was an independent risk factor for spontaneous abortion. It is now believed that women with pSS have significantly prolonged menstrual cycles, decreased pregnancy success, and can develop immune infertility. pSS is a common cause of immune infertility, where antinuclear antibodies, anti-SSA, and anti-SSB bind to the antigen and attack the embryo, leading to difficulty in implantation or miscarriage. A systematic review with the meta-analysis by Upala et al. showed that there was an increased risk of neonatal death and fetal loss in pregnant patients with pSS, but there was no statistical difference in the incidence of premature birth, or stillbirth between pSS and normal pregnant women. The number of papers included in the study by Upala et al. was fewer than that in this study, and half of them were published before 2000, and the incidence of birth

| Author     | Year of publication | Study type | Age (years) | Sample size | Pregnancy outcome                                      | NOS |
|------------|---------------------|------------|-------------|-------------|--------------------------------------------------------|-----|
| C Ballester | 2017                | Retrospective | 30.8±6.2 | 54          | Spontaneous abortion, preterm birth, low birth weight | 7   |
| Li         | 2019                | Prospective | 30.4±5.3  | 48          | Spontaneous abortion, preterm birth                    | 7   |
| S De Carolis | 2014              | Retrospective | 34.8    | 34          | Spontaneous abortion, preterm birth, low birth weight  | 6   |
| R Priori   | 2014                | Retrospective | Not described | 12          | Premature birth                                         | 5   |
| B Elliott  | 2019                | Retrospective | Not described | 1451±1640  | Premature birth, congenital malformations              | 6   |
| Yang, Jingjing | 2021          | Prospective | 31.89±3.55 | 56          | Spontaneous abortion, premature birth, and            | 7   |
| H J Haga   | 2005                | Retrospective | 26      | 36          | Spontaneous abortion, preterm birth, low birth weight, congenital malformations | 7   |
| E Hussein  | 2011                | Retrospective | 33.6±4.2 | 16          | Spontaneous abortion, preterm birth, low birth mass, congenital malformations | 7   |
| JF Xu      | 2019                | Retrospective | 32.0±4.3 | 64          | Spontaneous abortion, preterm birth, low birth mass, congenital malformations | 6   |
defects and low birth mass was not reported. The present study enrolled the papers in recent years and analyzed the common adverse pregnancy outcomes related to pSS. The correlation between pSS and spontaneous abortion was reported in five papers in the present study, and the results of the meta-analysis showed that the risk of spontaneous abortion in pSS pregnant women was 8.85 times higher than that of healthy pregnant women, and the risk of spontaneous abortion in pSS pregnant women was significantly increased. The above results suggest that clinical interventions should be actively carried out in women with SS during the preparation period and early pregnancy, but it is uncertain whether SS-related clinical interventions can improve pregnancy success and reduce the spontaneous abortion rate, and further clinical studies are needed to provide evidence.

SS can also have multiple negative effects on neonatal outcomes. Compared to healthy pregnant women, SS women have shorter gestation times, a higher incidence of preterm delivery, a lower percentile birth weight, and a higher proportion of Small for Gestational Age (SGA) infants. A cohort study by Chen JS et al. showed an increased incidence of acute adverse events such as hypertensive disorders and cerebral hemorrhage during pregnancy, a significantly higher incidence of preterm delivery and low birth weight, and a corresponding increase in the cesarean delivery rate in SS and SLE pregnant women. On one hand, SS can directly damage the placenta and affect fetal development and health; on the other hand, SS can increase the risk of complications and adverse events during pregnancy, all of which can lead to adverse pregnancy outcomes such as preterm delivery, low birth weight, neonatal asphyxia, and hypoxic-ischemic encephalopathy. The present study showed that pSS pregnancies experience an increased incidence of preterm delivery and low birth weight, and this correlation remained significant in sensitivity analysis, which further confirms the effect of SS on adverse pregnancy outcomes.

It was found that SS can also increase the risk of birth defects such as congenital heart disease. Circulating antibodies in pregnant women with SS can cause the development of congenital heart block in the fetus.
requiring pacemaker implantation in the newborn in severe cases. Therefore, the functional and structural characteristics of the fetal/neonatal heart should be highly monitored during the perinatal period and appropriate interventions should be given in a timely manner. Antibodies such as antinuclear, anti-SSA, and anti-SSB are the main antibodies mediating tissue damage in SS patients and are important factors predisposing to pregnancy complications. These antibodies can cross the placenta at 12 weeks of gestation and induce myocarditis and arrhythmias after acting on fetal myocardial tissue. In a study by Doti PI et al., the risk of congenital conduction block in the fetus of a pregnant woman with SS was higher than in pregnant women with other autoimmune diseases. Studies have shown that human fetal heart perfusion with anti-SSA can lead to transient heart block, mainly probably because anti-SSA can cross-react with T- and L-type calcium channels and the aforementioned reactions can also cause structural damage to the heart. It has also been shown that fetal atrial wall and annular echogenicity enhancement on ultrasound during pregnancy is associated with SS. The current study showed that pSS increased the risk of birth defects.

Table 2
Results of sensitivity analysis.

| Adverse pregnancy outcome | Before sensitivity analysis RR (95% CI) | Exclusion of literature with the largest RR | Exclusion of literature with the smallest RR |
|---------------------------|----------------------------------------|-------------------------------------------|-------------------------------------------|
| Spontaneous abortion      | 8.85 (3.10–25.26)                     | C Ballester (5.73 (3.09–10.65))           | Yang Jingjing (10.99 (3.79, 31.82))       |
| Premature birth           | 2.27 (1.46, 3.52)                     | JF Xu (2.04 (1.33, 3.23))                 | R Priori (2.46 (1.54, 3.92))              |
| Low birth weight          | 1.99 (1.34, 2.97)                     | S De Carolis (1.74 (1.11, 2.73))          | C Ballester (2.52 (1.61, 3.94))           |
| Birth defects             | 4.28 (3.08, 5.96)                     | JF Xu (3.77 (2.49, 5.99))                 | HJ Haga (2.25 (1.81, 37.61))              |

Figure 4. Correlation between pSS and low birth weight.

Figure 5. Correlation between pSS and birth defects.
suggesting that for pregnant women with SS, obstetric clinics should enhance prenatal consultations and early detection of congenital malformations to reduce birth defects.

In conclusion, SS can increase the risk of spontaneous abortion, preterm delivery, low birth weight, and birth defects, and the clinic should provide scientific and comprehensive preconception counseling and prenatal testing for female patients with SS, actively treat SS and gestational comorbidities, detect birth defects at an early stage, and choose the appropriate timing and mode of pregnancy termination to improve the prognosis of pregnant women and newborns. However, it is important to note that the existing studies on the association between SS and adverse pregnancy outcomes are relatively few, and most of the existing studies have failed to adequately manage confounding factors. On the other hand, this meta-analysis did not include articles written in other languages except for Chinese and English, which may lead to selection bias. Researchers still need to further analyze the association between SS and adverse pregnancy outcomes through high-quality cohort studies to provide a basis for the development of clinical intervention strategies.

Authors’ contributions

Baoqing Geng, Keyue Zhang and Yong Chen designed and performed the experiments. Qianqian Huang and Yong Chen performed the experiments and analyzed the data. Baoqing Geng and Yong Chen wrote and revised the manuscript.

Funding

No funding was received.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

None.

References

1. Cartee DL, Maker S, Dalonges D, Manski MC. Sjogren’s syndrome: oral manifestations and treatment, a dental perspective. J Dent Hyg 2015;89(6):365–71.
2. Ye W, Chen S, Huang X, Qin W, Zhang T, Zhu X, et al. Clinical features and risk factors of neurological involvement in Sjogren’s syndrome. BMC Neurosci 2018;19(1):26.
3. Pariziu D, Chivaso C, Perret J, Soyfno MS, Delpoer C. Current State of knowledge on primary sjogren’s syndrome, an autoimmune exocrinopathy. J Clin Med 2020;9(7):2299.
4. Bayetto K, Logan RM. Sjogren’s syndrome: a review of aetiology, pathogenesis, diagnosis and management. Aust Dent J 2010;55(S1 Supp):39–47.
5. Demarchi J, Papaiidero SB, Klajn D, Alba P, Babini AM, Durigan V, et al. Primary Sjogren’s syndrome and pregnancy: A report of 18 cases. Reumatol Clin (Eng Ed) 2019;15(2):109–12.
6. Page MJ, McKenzie JE, Bosnyt PM, Bouton I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
7. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford; 2000.
8. Yang J, Liang M. Analysis of maternal and child outcomes and associated factors in patients with combined dry syndrome of pregnancy. Chin J Obstetrics Gynecol 2021;22(3):228–30.
9. Li L. Clinical analysis of pregnancy outcomes in 48 women with dry syndrome pregnancies. J Clin Pathol Sci 2019;39(3):587–91.
10. Gliotti B, Spence AR, Cuzzol-Shulman N, Alberthim HA. Effect of Sjogren’s syndrome on maternal and neonatal outcomes of pregnancy. J Perinat Med 2019;47(6):637–42.
11. Ballester C, Grobost V, Roblot P, Pourrat O, Pierre F, Laurichesse-Delmas H, et al. Pregnancy and primary Sjogren’s syndrome: management and outcomes in a multicentre retrospective study of 54 pregnancies. Scand J Rheumatol 2017;46(1):56–63.
12. De Carolis S, Silvi S, Botta A, Garofalo S, Garufi C, Ferrazzani S, et al. The impact of primary Sjogren’s syndrome on pregnancy outcome: our series and review of the literature. Autoimmun Rev 2014;13(2):103–7.
13. Priori R, Gattamelata A, Modesti M, Calafarnecco S, Fisenda S, Minniti A, et al. Outcome of pregnancy in Italian patients with primary Sjogren syndrome. J Rheumatol 2013;40(7):1143–7.
14. Haga HJ, Gledsal G, Kokrikov HS, Skromvoll JF, Irgens LM, Ostensen M. Pregnancy outcome in patients with primary Sjogren’s syndrome: a case-control study. J Rheumatol 2005;32(9):1734–6.
15. Hussein SZ, Jacobsson LT, Lindquist PG, Theander E. Pregnancy and fetal outcome in women with combined primary Sjogren’s syndrome. Clin Rev Allergy Immunol 2016;50(4):293–301.
16. Xu J, Chen D, Tian Y, Peng B. Pregnancy outcomes with primary Sjogren’s syndrome among Chinese women: a retrospective cohort study. Res Square 2019. https://doi.org/10.21203/rs.2.14389/v1.
17. Miyasato-Isoda M, Waguiri M, Yamada Y, Miyano A, Wada Y. Anti-Ro52 antibody level is an important marker of fetal congenital heart block risk in anti-Ro/SSA antibody positive pregnancy. Mod Rheumatol 2018;28(4):690–6.
18. Frit H, Mackelkorn U, Dorner T, Donitz H, Schaeffer S, Heige F, et al. Autoantibodies in primary Sjogren’s syndrome are directed against proterosomal subunits of the alpha and beta type. Arthritis Rheum 1999;42(4):697–702.
19. Komaru Y, Higuchi T, Koyama H, Haji Y, Oka M, Kamesaki T, et al. Primary Sjogren’s syndrome presenting with hemolytic anemia and pure red cell aplasia following delivery due to Coombs-negative autoimmune hemolytic anemia and hemophagocytosis. Intern Med 2013;52(20):2343–6.
20. Ibiru Talabi M, Himes KP, Clove ME. Optimizing reproductive health management in lupus and Sjogren’s syndrome. Curr Opin Rheumatol 2021;33(1):57–63.
21. Chen L, Shang LX, Huang Y. Immune infertility and immune-related recurrent miscarriage. People’s Army Medical 2019;62(7):665–9. 74.
22. Upala S, Yong WC, Sangamakoo A. Association between primary Sjogren’s syndrome and pregnancy complications: a systematic review and meta-analysis. Clin Rheumatol 2016;35(8):1949–55.
23. Chen JS, Roberts CL, Simpson JM, March LM. Pregnancy Outcomes in Women With Antiphospholipid Syndrome. Obstet Gynecol 2015;125(2):331–23.
24. Kim NE, Lee JH, Chung IS, Lee JY. Anesthetic management of patient with Sjogren’s syndrome who underwent cesarean section: a case report. Korean J Anesthesiol 2016;69(3):283–6.
25. Bucatini A, Gimaz R, Caponcil N, Ramoni V, Buon J. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clin Rev Allergy Immunol 2011;40(1):27–41.
26. Doti PI, Escuda O, Cesar-Diez S, Palasti S, Teixido I, Sarquella-Bruguada G, et al. Congenital heart block related to maternal autoantibodies: descriptive analysis of a series of 18 cases from a single center. Clin Rheumatol 2016;35(2):351–6.
27. Tomimatsu T, Hazama Y, Takeuchi M, Kimura T, Shimoya K. Unresponsiveness to oxytocin due to an extremely thin uterine wall in a pregnant woman with systemic lupus erythematosus and Sjogren’s syndrome. J Obstet Gynecol 2018;38(2):276–8.
28. Sisto M, Ribatti D, Lis S. Understanding the Complexity of Sjogren’s Syndrome: Remarkable Progress in Elucidating NF-κB Mechanisms. J Clin Med 2020;9(9).
29. Liu XW, Sun L, Zhao Y. Association of echogenic enhancement of fetal atrial wall and annulus with maternal anti-desiccation antibody positivity on ultrasonography. Chin J Obstetrics Gynecol 2019;54(2):116–20.